Pablo Corral Shares New Insights: Genome Editing and Gene Therapy for Lipid Disorders
Pablo Corral, Past President of Argentine Lipid Society, has shared a post on LinkedIn:
“A must read article
‘Gene therapy and genome editing for lipoprotein disorders‘ provides a comprehensive and timely overview of how advances in genetic medicine—including AAV gene addition, CRISPR editing, and RNA-based strategies—are reshaping the prevention and management of dyslipidaemias and ASCVD.
This open-access article highlights how innovative approaches may overcome limitations of lifelong lipid-lowering therapy, address unmet clinical needs in familial and polygenic disorders, and integrate polygenic risk scores and machine learning to personalize cardiovascular prevention.
An excellent resource for clinicians, researchers, and students interested in the rapidly evolving field of cardiovascular genetics.”
Title: Gene therapy and genome editing for lipoprotein disorders
Authors: Chen Gurevitz, Archna Bajaj, Amit V Khera, Ron Do, Heribert Schunkert, Kiran Musunuru, Robert S Rosenson
Read the full paper here.
Stay informed with Hemostasis Today.
-
Feb 23, 2026, 18:13Fight4Hematology Supports Research and Empowers the Next Generation – ASH
-
Feb 23, 2026, 17:59Wolfgang Miesbach: Real-World Evidence of Emicizumab on Joint Outcomes in Hemophilia A
-
Feb 23, 2026, 17:56Shiny K Kajal: The Transfusion Reaction We Often Miss
-
Feb 23, 2026, 17:53Radheshyam Meher: Contributing to the Transfusion Evidence Round-Up for International Childhood Cancer Day 2026
-
Feb 23, 2026, 17:46Mahesan Subramaniam: The Physiological Impact of Anger on Immunity
-
Feb 23, 2026, 17:42Bryan Fry: First Evidence That Bothrops atrox Venom Directly Activates Human Factor VII
-
Feb 23, 2026, 17:34Bastu Odoka: Why Blood Should NOT be Left at the Bedside to ‘Warm’
-
Feb 23, 2026, 17:28Henry Burkitt: Patients Are Challenging How the Medicines Policy System Works in England
-
Feb 23, 2026, 16:50Mutaz Al‑Sabah: Interesting Webinar on FH in Women is Now Available to Watch